Abstracts tagged "Systemic sclerosis"

Abstract Number: L18 • ACR Convergence 2024
CCL19+ Fibroblasts Orchestrate Fibrotic Microenvironment via CCL19-CCR7 Axis in Systemic Sclerosis
Wei Guo¹, Zhaohua Li², Dan Xu² and Rong Mu², ¹Department of Rheumatology and Immunology, Peking University Third Hospital, Beijing, China, ²Peking University Third Hospital, Beijing, China
Background/Purpose: Understanding the roles of diverse fibroblast subsets is of great importance in elucidating the pathogenesis of fibrosis in systemic sclerosis (SSc). However, how the…
Abstract Number: 0706 • ACR Convergence 2024
Single Center Prospective Cohort of Systemic Sclerosis Patients Who Are At-Risk for Pulmonary Hypertension
Carleigh Zahn¹, Scott Visovatti², Rosemary Gedert¹, Suiyuan Huang¹, Victor Moles¹, Amber Young¹, Vallerie McLaughlin¹ and Dinesh Khanna¹, ¹University of Michigan, Ann Arbor, MI, ²The Ohio State University, Columbus
Background/Purpose: Pulmonary hypertension (PH) is a leading cause of mortality in systemic sclerosis (SSc). We launched an IRB approved prospective study (NOVEL) in 2013 at…
Abstract Number: 0958 • ACR Convergence 2024
TCR Motifs Identify Unique Clones in African Americans with Systemic Sclerosis
Urvashi Kaundal¹, Chloe Borden², Devin Teehan², Brittany Dulek³, Justin Lack⁴, Ami Shah⁵, Maureen Mayes⁶, Daniel Shriner⁷, Ayo P. Doumatey⁷, Amy Bentley⁷, Robyn Domsic⁸, Thomas Medsger, Jr⁹, Paula Ramos¹⁰, Richard Silver¹¹, Virginia Steen¹², John Varga¹³, Vivien Hsu¹⁴, Lesley Ann Saketkoo¹⁵, Dinesh Khanna¹³, Elena Schiopu¹⁶, Jessica Gordon¹⁷, Lindsey Criswell¹⁸, Heather Gladue¹⁹, Chris Derk²⁰, Elana Bernstein²¹, S. Louis Bridges¹⁷, Victoria Shanmugam²², Lorinda Chung²³, Suzanne Kafaja²⁴, Reem Jan²⁵, Marcin Trojanowski²⁶, Avram Goldberg²⁷, Benjamin Korman²⁸, Faiza Naz²⁹, Stefania Dell'Orso³⁰, Adebowale Adeyemo⁷, Elaine Remmers³¹, Charles Rotimi⁷, Fredrick Wigley³², Francesco Boin³³, Daniel Kastner³⁴ and Pravitt Gourh²⁹, ¹Scleroderma Genomics and Health Disparities Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Chevy Chase, MD, ²Scleroderma Genomics and Health Disparities Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ³Integrated Data Science Section, Research Technologies Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, ⁴Integrated Data Science Section, Research Technologies Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, Bethesda, MD, ⁵Division of Rheumatology, Johns Hopkins University, Ellicott City, MD, ⁶UTHealth Houston Division of Rheumatology, Houston, TX, ⁷Center for Research on Genomics and Global Health, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ⁸Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁹Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Verona, PA, ¹⁰Medical University of South Carolina, Charleston, SC, ¹¹Division of Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, ¹²Georgetown University School of Medicine, Washington, DC, ¹³University of Michigan, Ann Arbor, MI, ¹⁴Department of Medicine, Rheumatology Division, Rutgers-RWJ Medical School, South Plainfield, NJ, ¹⁵New Orleans Scleroderma and Sarcoidosis Patient Care and Research Center, Louisiana State University and Tulane University Medical Schools, New Orleans, LA, ¹⁶Division of Rheumatology, Medical College of Georgia at Augusta University, Martinez, GA, ¹⁷Division of Rheumatology, Weill Cornell Medical College, New York, NY, ¹⁸Genomics of Autoimmune Rheumatic Disease Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, Bethesda, MD, ¹⁹Arthritis & Osteoporosis Consultants of the Carolinas, Charlotte, NC, ²⁰Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ²¹Division of Rheumatology, Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, ²²NIH Office of Autoimmune Disease Research in the Office of Research on Women's Health, National Institutes of Health, Bethesda, MD, Bethesda, MD, ²³Stanford University, Woodside, CA, ²⁴Division of Rheumatology, University of California, Los Angeles, Los Angeles, CA, ²⁵Section of Rheumatology, Department of Medicine, University of Chicago, Chicago, IL, ²⁶Department of Rheumatology, Boston University School of Medicine, Boston, MA, ²⁷NYU Langone Health - NYU Hospital for Joint Diseases, Lake Success, NY, ²⁸University of Rochester, Rochester, NY, ²⁹National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, Bethesda, MD, ³⁰Genomic Technology Section, Office of Science and Technology, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ³¹Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ³²Johns Hopkins University, Division of Rheumatology, Baltimore, MD, Baltimore, MD, ³³Cedars-Sinai Medical Center, Los Angeles, CA, ³⁴National Human Genome Research Institute, Bethesda, MD
Background/Purpose: Systemic sclerosis (SSc) is a rare multisystem autoimmune disease that disproportionately affects African Americans (AA). Previous work from our lab has suggested a pivotal…
Abstract Number: 1561 • ACR Convergence 2024
Association of Large Vessel Vasculitis and Development of SSc and SSc-Associated Antibodies: Impact of Pulmonary Arterial Hypertension
Brett Dinner¹, Ahmed Abdelmaksoud², Ann Igoe³, Taylor Viggiano⁴ and Vivek Nagaraja⁵, ¹Creighton University, Paradise Valley, AZ, ²University of California, Riverside, Riverside, CA, ³Flow, Tempe, AZ, ⁴Mayo Clinic, Phoenix, ⁵Mayo Clinic Arizona, Scottsdale, AZ
Background/Purpose: Large vessel vasculitis (LVV) comprises a spectrum of rare, potentially life-threatening disorders, including giant cell arteritis (GCA) and Takayasu's arteritis (TAK), defined by granulomatous…
Abstract Number: 1587 • ACR Convergence 2024
Predictors of Body Mass Index in an Early Systemic Sclerosis Cohort
Ali Ayla¹, Meng Zhang¹, Claudia Pedroza², Bingrui Chen², Brian Skaug¹, Maureen Mayes¹, Shervin Assassi¹ and Zsuzsanna McMahan¹, ¹UTHealth Houston Division of Rheumatology, Houston, TX, ²UTHealth Houston, Houston, TX
Background/Purpose: Malnutrition is a significant problem among patients with systemic sclerosis (SSc). Body mass index (BMI) is often low in patients with malnutrition. Low BMI…
Abstract Number: 1824 • ACR Convergence 2024
Skin Macrophage Subtypes and Impact of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis: Results from Single-cell Analyses of an Observational Data Set and a Phase I/II Randomized Controlled Trial
Juliette Ferrant¹, Alain Lescoat², Valérie Lecureur³, Marie Lelong³, John Varga⁴, Robert Lafyatis⁵, Johann Gudjonsson⁴ and Dinesh Khanna⁴, ¹CHU Rennes, Rennes, France, ²CHU Rennes - University Rennes 1, Rennes, France, ³Rennes University, Rennes, France, ⁴University of Michigan, Ann Arbor, MI, ⁵University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Macrophages play a major role in dcSSc-related skin fibrosis, with a mixed M1-M2 activation profile relying on the activation of JAK/STAT. Tofacitinib, a pan-JAK…
Abstract Number: 2207 • ACR Convergence 2024
Improvement Across Physician and Patient Reported Outcome Measures over a 24 Months-time Period in the Juvenile Systemic Scleroderma Inception Cohort
Ivan Foeldvari¹, Jens Klotsche², Ozgur Kasapcopur³, Amra Adrovic⁴, Kathryn Torok⁵, Maria Teresa Terreri⁶, Ana Sakamoto⁷, Jordi Anton⁸, Brian Feldman⁹, Raju Khubchandani¹⁰, Tadey Avcin¹¹, Sindhu R. Johnson¹², Mikhail Kostik¹³, Edoardo Marrani¹⁴, Flavio Sztajnbok¹⁵, Maria Katsicas¹⁶, Dana Nemcova¹⁷, Maria Jose Santos¹⁸, Simone Appenzeller¹⁹, Cristina Battagliotti²⁰, Lillemor Berntson²¹, Jürgen Brunner²², Liora Harel²³, Gerd Horneff²⁴, Tilmann Kallinich²⁵, Kirsten Minden², Farzana Nuruzzaman²⁶, Anjali Patwardhan²⁷, Dieneke Schonenberg-Meinema²⁸ and Nicola Helmus²⁹, ¹Hamburger Zentrum für Kinder- und Jugendrheumatologie, Hamburg, Germany, ²German Rheumatism Research Center, Berlin, Germany, ³Istanbul University-Cerrahpasa, Cerrahpasa Medical School, istanbul, Turkey, ⁴Cerrahpasa Medical School, Istanbul, Turkey, ⁵Division of Rheumatology, Scleroderma Center, Department of Pediatrics, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA, ⁶UNIFESP, São Paulo, SP, Brazil, ⁷Federal University of São Paulo (UNIFESP), São Paulo, SP, Brazil, ⁸Hospital Sant Joan de Déu. Universitat de Barcelona, Esplugues de Llobregat (Barcelona), Spain, ⁹Division of Rheumatology, The Hospital for Sick Children; Departments of Pediatrics and Medicine, Faculty of Medicine; The Institute for Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, ¹⁰SRCC Childrens Hospital, Mumbai, India, ¹¹University Children's Hospital University Medical Center Ljubljana, Ljubljana, Slovenia, ¹²University of Toronto, Toronto, Canada, ¹³Saint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia, ¹⁴University of Florence, Firenze, Florence, Italy, ¹⁵UFRJ/UERJ, SAO PAULO, Brazil, ¹⁶Hospital Garrahan, Buenos Aires, Argentina, ¹⁷MD, Prague, Czech Republic, ¹⁸Hospital Garcia de Orta and Centro Académico de Medicina de Lisboa, Lisboa, Portugal, ¹⁹Unicamp, Campinas, SP, Brazil, ²⁰Hospital de Niños Dr Orlando Alassia, Santa Fe, Argentina, ²¹Dept. of Women’s and Children’s Health, Uppsala University, Uppsala, Sweden, ²²Medical University Innsbruck; Department of Pediatrics, Pediatric Rheumatology, Innsbruck, Austria, ²³Faculty of Medicine, Tel Aviv University, Tel Aviv; Pediatric Rheumatology Unit, Schneider Children's Medical Center of Israel, Petach Tikva, Israel, Petach Tikva, HaMerkaz, Israel, ²⁴Asklepios Klinik Sankt Augustin GmbH, Sankt Augustin, Germany, ²⁵Charite, Berlin, Germany, ²⁶Stony Brook Children's Hospital, Stony Brook, NY, ²⁷University of Missouri-Columbia, Department of Child Health, 404 N Keene Street, Columbia MO 65210, Columbia, ²⁸Emma Children’s Hospital, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands, ²⁹Hamburg Centre for Pediatric and Adolescence Rheumatology, Hamburg, Germany
Background/Purpose: Juvenile systemic sclerosis (jSSc) is an orphan disease with a prevalence of 3 in 1 000 000 children. The Juvenile Systemic Scleroderma Inception cohort…
Abstract Number: 2470 • ACR Convergence 2024
Progression Patterns in Systemic Sclerosis – Associated Interstitial Lung Diseases
anais Roeser¹, Pierre-Yves Brillet¹, Marouane Boubaya¹, Frédéric Caux¹, Robin Dhote¹, Hilario Nunes¹ and Yurdagül Uzunhan², ¹APHP, Bobigny, France, ²Service de Pneumologie, Hôpital Avicenne, AP-HP, Bobigny, France
Background/Purpose: The occurrence of interstitial lung disease (ILD) in the course of systemic sclerosis (SSc) is associated with increased morbidity and mortality. SSc-ILD evolution is…
Abstract Number: 0247 • ACR Convergence 2024
Enhanced Immunogenicity of the Recombinant Herpes Zoster Vaccine After One-Week of Mycophenolate Mofetil Discontinuation in Patients with Autoimmune Rheumatic Diseases: Interim Results from a Prospective Randomized Phase 4 Study
Sandra Pasoto¹, Isabele Antonelli¹, Ana Cristina Medeiros-Ribeiro², Nadia Aikawa³, Leonard Kupa¹, Eduardo Borba¹, Luciana Seguro⁴, Emily Figueiredo Neves Yuki¹, ANA PAULA ASSAD¹, Carla Saad⁴, Andrea Shimabuco⁴, Andrea Negrini¹, Julia Medeiros¹, Talita Ribeiro¹, Samuel Shinjo⁴, Percival Sampaio-Barros⁴, Danieli Andrade⁵, Fernando Souza⁴, Renata Miossi⁴, Clovis Silva⁶ and Eloisa Bonfa¹, ¹Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, ²Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Jose Dos Campos, Brazil, ³Rheumatology Division and Pediatric Rheumatology Unit, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil, ⁴Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, SP, Brazil, ⁵University of São Paulo, São Paulo, SP, Brazil, ⁶Rheumatology Division and Pediatric Rheumatology Unit, Instituto da Criança e do Adolescente, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, SP, Brazil
Background/Purpose: Recently, it was demonstrated that temporarily halting mycophenolate mofetil (MMF) for 1-week post-COVID-19 vaccination in systemic lupus erythematosus (SLE) patients improved humoral response, without…
Abstract Number: 0707 • ACR Convergence 2024
Comprehensive Skin Assessment in Systemic Sclerosis Using Spatial Frequency Domain Imaging (SFDI)
Hung Vo¹, Aarohi Mehendale², Mahendra Chaudhari³, Fatima El adili³, Jeffrey Browning⁴, Michael York⁵, Marcin Trojanowski⁶, Eugene Kissin⁷, Darren Roblyer² and Andreea Bujor⁵, ¹Boston Medical Center, Peabody, MA, ²Department of Biomedical Engineering, Boston University, Boston, MA, ³Boston Medical Center, Boston, MA, ⁴Boston University, Cambridge, MA, ⁵Boston University, Boston, MA, ⁶Department of Rheumatology, Boston University School of Medicine, Boston, MA, ⁷Boston University, Newton, MA
Background/Purpose: The modified Rodnan skin score (mRSS) is the gold standard for scleroderma (SSc) skin assessment, yet it suffers from subjectivity and interrater variability. Spatial…
Abstract Number: 0959 • ACR Convergence 2024
Radiomics Non-Invasively Conveys Time-Resolved Molecular Pathway Activity in Experimental Fibrosing Interstitial Lung Disease
David Lauer¹, Matthias Brunner², Hubert Gabrys³, Kerstin Klein², Oliver Distler⁴, Britta Maurer⁵ and Janine Gote-Schniering², ¹University Hospital Bern, Bern, Switzerland, ²University of Bern, Bern, Switzerland, ³University Hospital Zurich, Zurich, Zurich, Switzerland, ⁴Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Zurich, Switzerland, ⁵University Hospital Bern, University Bern, Bern, Switzerland
Background/Purpose: Interstitial lung disease (ILD) is a major cause of mortality in patients with autoimmune-related CTD such as SSc and RA. Molecular characterization of the…
Abstract Number: 1565 • ACR Convergence 2024
Prevalence and Risk Factors of Lower Extremities Arterial Disease in Systemic Sclerosis: Preliminary Data from a Single Centre Multidisciplinary Study
Maria-Grazia Lazzaroni¹, Paolo Baggi², Liala Moschetti¹, Eleonora Pedretti³, Elda Piovani¹, Claudia Barison¹, Emma Manzoni⁴, Franco Franceschini¹, Stefano Bonardelli² and Paolo Airò¹, ¹Scleroderma Unit, Rheumatology and Clinical Immunology Unit, ERN ReCONNET, ASST Spedali Civili, Brescia, Italy, Brescia, Italy, ²Vascular Surgery Unit, ASST Spedali Civili of Brescia, University of Brescia, Italy, Brescia, Italy, ³Scleroderma Unit, Rheumatology Unit, ERN ReCONNET, ASST Spedali Civili and University of Brescia; Italy, Brescia, Italy, ⁴University of Brescia, Brescia, Italy
Background/Purpose: Microvascular changes represent a key step of pathogenic process in Systemic Sclerosis (SSc). However, SSc has been demonstrated to carry an increased risk of…
Abstract Number: 1589 • ACR Convergence 2024
Whole Skin Gene Expression Analysis Identifies Discrete Modules That Differentiate Antinuclear Antibody Subsets in Systemic Sclerosis
Kristina Clark¹, Corrado Campochiaro², Philip Yee³, Emma Derrett-Smith⁴, Voon Ong⁵ and Christopher Denton⁶, ¹University of Oxford, Oxford, United Kingdom, ²IRCCS San Raffaele Hospital. Vita-Salute San Raffaele University, Milan, Milan, Italy, ³UCL, London, United Kingdom, ⁴University College London Division of Medicine, Birmingham, United Kingdom, ⁵University College London, London, England, United Kingdom, ⁶University College London, Northwood, United Kingdom
Background/Purpose: Hallmark autoantibody reactivities predict different patterns of skin involvement and risk of internal organ involvement. We have asked whether whole skin gene expression may…
Abstract Number: 1826 • ACR Convergence 2024
Unveiling the Primary Cilia Signature Driving Systemic Sclerosis Pathogenesis
Le My Tu Nguyen¹, Carlos Córdova-Fletes², Poulami Dey³, Johann Gudjonsson³, Rebecca Wells⁴, Rebecca Ross⁵, Natalia Riobo-Del Galdo⁴, Francesco Del Galdo⁴, Dibyendu Bhattacharyya³, John Varga³ and Maria Teves¹, ¹Virginia Commonwealth University, Richmond, VA, ²Universidad Autónoma de Nuevo León, Monterrey, Mexico, ³University of Michigan, Ann Arbor, MI, ⁴University of Leeds, Leeds, United Kingdom, ⁵Medicine and Health, University of Leeds, Leeds, United Kingdom
Background/Purpose: Fibrosis in multiple organs is the defining hallmark that accounts for the high mortality associated with systemic sclerosis (SSc). Understanding how SSc patients develop…
Abstract Number: 2443 • ACR Convergence 2024
The Clinical Phenotype of Anti-Th/To+ Patients in Systemic Sclerosis: A Case-control Study Within the European Scleroderma Trials and Research (EUSTAR) Cohort
Liala Moschetti¹, Eleonora Pedretti², Francesco Bonomi³, María Martín López⁴, Fabio Cacciapaglia⁵, cristiana sieiro santos⁶, Gianluca Moroncini⁷, Yannick Allanore⁸, Joana Caetano⁹, Brigitte Granel¹⁰, Laura Groseanu¹¹, Maria De Santis¹², Masataka Kuwana¹³, Veronica Codullo¹⁴, Mariana Pereira Silva¹⁵, Pietro Bearzi¹⁶, Laura Belloli¹⁷, Alida Taberner-Cortés¹⁸, Cristina Maglio¹⁹, Francesco Del Galdo²⁰, Corrado Campochiaro²¹, Marie-Elise Truchetet²², Giovanna Cuomo²³, Magda Parvu²⁴, Florenzo Iannone²⁵, Patricia Carreira²⁶, Serena Guiducci²⁷, Franco Franceschini¹, Paolo Airò¹ and Maria-Grazia Lazzaroni¹, ¹Scleroderma Unit, Rheumatology and Clinical Immunology Unit, ERN ReCONNET, ASST Spedali Civili, Brescia, Italy, Brescia, Italy, ²Scleroderma Unit, Rheumatology Unit, ERN ReCONNET, ASST Spedali Civili and University of Brescia; Italy, Brescia, Italy, ³Division of Rheumatology, Scleroderma Unit, University of Florence, AOU Careggi Firenze; Italy, Firenze, Italy, ⁴General University Hospital of Ciudad Real, Ciudad de México, Spain, ⁵Rheumatology Unit � DiMePRe-J, University and AOU Policlinico of Bari, Italy, Bari, Italy, ⁶Rheumatology Department, Complejo Asistencial Universitario de León, León, Spain, Leon, Spain, ⁷Marche Polytechnic University, Ancona, Italy, ⁸Rheumatology department, Université Paris Cité, Cochin Hospital of Paris; France, Paris, France, ⁹Systemic Autoimmune Diseases Unit, Fernando Fonseca Hospital, Amadora; Portugal, Amadora, Portugal, ¹⁰Service de Médecine Interne Hôpital Nord de Marseille; France, Marseille, France, ¹¹Spitalul Sfanta Maria, Bucharest, Romania, ¹²Rheumatology and Clinical Immunology, IRCCS Humanitas Research Hospital and Biomedical Sciences, Hu-manitas University, Milan; Italy, Milan, Italy, ¹³Department of Allergy and Rheumatology, Nippon Medical School, Tokyo, Japan, Tokyo, Japan, ¹⁴Unit of Rheumatology, San Matteo Hospital, Pavia, Italy, ¹⁵Rheumatology Department, Unidade Local de Saúde Santa Maria, Centro Académico de Medicina de Lisboa; Portugal, Lisboa, Portugal, ¹⁶Immunorheumatology Unit, Università Campus Bio-Medico University of Roma; Italy, Roma, Italy, ¹⁷Niguarda Hospital, Milan, Milan, Italy, ¹⁸Hospital Universitario Doctor Peset, Valencia, Spain, ¹⁹University of Gothenburg, Gothenburg, Sweden, ²⁰University of Leeds, Leeds, United Kingdom, ²¹IRCCS San Raffaele Hospital. Vita-Salute San Raffaele University, Milan, Milan, Italy, ²²Bordeaux University Hospital, Bordeaux, France, ²³Università degli studi della Campania Luigi Vanvitelli, Napoli, Italy, ²⁴Colentina Clinical Hospital, Rheumatology Department, Bucharest; Romania, Bucharest, Romania, ²⁵Rheumatology Unit- University of Bari "Aldo Moro", IT, Bari, Italy, ²⁶Hospital Universitario 12 de Octubre, Madrid, Madrid, Spain, ²⁷Division of Rheumatology, Scleroderma Unit, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
Background/Purpose: To evaluate clinical associations of anti-Th/To antibodies in SSc patients in a multicentre international cohort, focusing on interstitial lung disease (ILD), pulmonary arterial hypertension…

1
2
3
…
46
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].